- Home
- KROS vs MNPR Comparison
KROS vs MNPR Comparison
Compare KROS & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KROS | MNPR |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 565.0M | 531.6M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | KROS | MNPR |
|---|---|---|
| Price | $17.46 | $86.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $22.20 | ★ $97.83 |
| AVG Volume (30 Days) | ★ 1.3M | 160.7K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $246,718,000.00 | N/A |
| Revenue This Year | $6,657.47 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.10 | ★ N/A |
| Revenue Growth | ★ 37798.31 | N/A |
| 52 Week Low | $9.12 | $19.87 |
| 52 Week High | $72.37 | $105.00 |
Technical Indicators
Market Signals| Indicator | KROS | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 62.55 | 51.97 |
| Support Level | $16.63 | $83.86 |
| Resistance Level | $17.73 | $100.50 |
| Average True Range (ATR) | 0.78 | 7.88 |
| MACD | 0.02 | 0.28 |
| Stochastic Oscillator | 55.71 | 40.97 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.